Benchmarking Pharmaceutical Planning Valuation 
Barry Ritholtz
MARCH 14, 2023
Everybody wants to sell a company when they get a good valuation. Obviously, profits, very important to company valuation — BERNSTEIN: Absolutely. The other thing we do, Barry, is we group valuation as a sentiment indicator. So we do a lot of valuation work. BERNSTEIN: Correct. RITHOLTZ: Right. BERNSTEIN: Exactly.
Barry Ritholtz
DECEMBER 12, 2023
He has absolutely crushed his benchmark over that period. He’s crushed the Russell 2000, whatever benchmark you want to talk about. And the division that I was in was below plan. So it leads to the question, what’s the secret to this longstanding outperformance against all benchmarks and, and all passive measures?
Expert insights. Personalized for you.
61 
Let's personalize your content